Korea bio-backed companies rush towards Nasdaq after Coupang feat
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
According to market experts on Tuesday, ImmuneOncia Therapeutics, a joint venture between Yuhan Corporation and U.S. Sorrento Therapeutics, and Artiva Biotherapeutics, a U.S. affiliate of GC LabCell, are strong candidates to join the tech-heavy market given their drug development capabilities recognized globally.
ImmuneOncia, a clinical-stage, immuno-oncology company, last month announced an exclusive license agreement worth 532 billion won ($472 million) with China’s 3D Medicines for the development, manufacture and commercialization of ImmuneOncia's monoclonal antibody.
ImmuneOncia jointly established by Yuhan and Nasdaq-listed Sorrento Therapeutics in 2016 is conducting a phase 2 clinical trial of IMC-001, a PD-L1 monoclonal antibody, in Korea and a phase 1 study in the U.S.
Unlike ImmuneOncia’s direct IPO method, Artiva Biotherapeutics is preparing to go public as a U.S. operation. Artiva Biotherapeutics was established in the U.S. by Korea’s GC and GC LabCell in 2019 for global R&D projects. According to GC LabCell, the Korean companies filed for IPO of Artiva on the New York Stock Exchange last week.
CoImmune, a joint venture established in the U.S. by Korea’s SCM Lifescience and Genexine, is another Korean bio name preparing to get listed on the Nasdaq. CoImmune is developing novel therapies leukemia and other highly unmet diseases.
Aprogen recently signed an advisory contract with Nomura Securities to seek its IPO on the Nasdaq. ROKIT Healthcare, L&K BIOMED, and Dong-A ST are among those considering their Nasdaq debut by acquiring a controlling stake in U.S. operations.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Korea’s antitrust agency seeks revisions to make consumer class suits easier - Pulse by Maeil Business News Korea
- Bithumb deposit triples in one year thanks to booming cryptocurrency investment - Pulse by Maeil Business News Korea
- Samsung takes home 71 awards from iF Design Award - Pulse by Maeil Business News Korea
- Thelma Therapeutics’ Phase 3 IND for Covid-19 cure rejected in Korea - Pulse by Maeil Business News Korea
- Louis Vuitton, Hermès enjoy bumper pandemic year as Koreans lavish on luxuries - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- K뷰티 열풍에...M&A ‘큰 장’ 섰다
- 檢, ‘14살 트로트 가수’ 오유진 스토킹한 60대男 집유 선고에 항소 - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이